Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors

Jonathan G Pol (1, 2, 3, 4) , Sarah Levesque (1, 2, 3, 4) , Samuel T Workenhe (5) , Shashi Gujar (6) , Fabrice Le Boeuf (7, 8) , Derek R Clements (6) , Jean-Eudes Fahrner (1) , Laetitia Fend , John C. Bell (8, 7) , Karen L Mossman (5) , Jitka Fucikova (9, 10) , Radek Spisek (10, 9) , Laurence Zitvogel (1, 11) , Guido Kroemer (12, 1, 3, 2, 4, 13, 14) , Lorenzo Galluzzi (3, 15, 16)

1 IGR - Institut Gustave Roussy
2 CRC (UMR_S_1138 / U1138) - Centre de Recherche des Cordeliers
3 USPC - Université Sorbonne Paris Cité
4 Ligue Nationale Contre le Cancer - Paris
5 McMaster University [Hamilton, Ontario]
6 Dalhousie University [Halifax]
7 OHRI - Ottawa Hospital Research Institute [Ottawa]
8 University of Ottawa [Ottawa]
9 University Hospital Motol [Prague]
10 UK - Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic]
11 UMR 1015 - Immunologie des tumeurs et immunothérapie
12 Service de biologie [CHU HEGP]
13 Karolinska University Hospital [Stockholm]
14 Plateforme de métabolomique
15 Weill Medical College of Cornell University [New York]
16 Sandra and Edward Meyer Cancer Center [New-York]

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

Mots clés: Pexa- Vec; MV-NIS; Maraba MG1; HF10; Pexa-Vec; T-VEC; REOLYSIN; CAVATAK; DNX-2401

Domaines: Cancer; Immunothérapie

Jonathan G Pol, Sarah Levesque, Samuel T Workenhe, Shashi Gujar, Fabrice Le Boeuf, et al.. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology, 2018, 7 (12), pp.e1503032. ⟨10.1080/2162402X.2018.1503032⟩. ⟨hal-02174653⟩